Effect of methylprednisolone on the oxidative burst activity, adhesion molecules and clinical outcome following open heart surgery.
Following cardiac surgery with cardiopulmonary bypass (CPB), activated granulocytes may be involved with ischaemia/ reperfusion injury. The purpose of this study was to investigate whether steroids could reduce the oxidative burst activity of granulocytes, the expression of adhesion molecules on granulocytes and improve clinical outcome. Sixteen patients undergoing open heart surgery participated in the study. Eight were randomized to receive methylprednisolone (30 mg/kg intravenously) at the start of anaesthesia while eight patients served as a control group. The oxidative burst was measured flow cytometrically using 123-dihydrorhodamine. A panel of adhesion molecules was measured using monoclonal antibodies. Following CPB the oxidative burst activity and the expression of the adhesion molecule L-selectin more than doubled compared to initial values. There was no difference between the steroid group and the control group regarding the expression of adhesion molecules or the oxidative burst activity. In the steroid group the fluid gain during extracorporeal circulation (ECC) was 683 ml (median) compared to 1488 ml in the control group. Steroids prevented hyperthermia in the postoperative period but did not improve the weaning from the ventilator or reduce the stay in the intensive-care unit. In conclusion, treatment with steroids prevented hyperthermia following open heart surgery with CPB and reduced capillary leak during ECC. Methylprednisolone, however, did not reduce the oxidative burst activity or the expression of adhesion molecules on granulocytes following CPB.
Toft
P
P
Department of Anaesthesiology and Intensive Care, University Hospital of Arhus, Denmark.
Christiansen
K
K
Tønnesen
E
E
Nielsen
C H
CH
Lillevang
S
S
D019559:Capillary Leak Syndrome / Q000517:prevention & control; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass; D015815:Cell Adhesion Molecules / Q000096:biosynthesis / Q000187:drug effects*; D005260:Female; D005334:Fever / Q000517:prevention & control; D005938:Glucocorticoids / Q000627:therapeutic use*; D006098:Granulocytes / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D015428:Myocardial Reperfusion Injury / Q000276:immunology / Q000517:prevention & control*; D016897:Respiratory Burst / Q000187:drug effects*
D015815:Cell Adhesion Molecules; D005938:Glucocorticoids; D008775:Methylprednisolone